Literature DB >> 9351394

Tissue factor expression on macrophages in coronary plaques in patients with unstable angina.

K Kaikita1, H Ogawa, H Yasue, M Takeya, K Takahashi, T Saito, K Hayasaki, K Horiuchi, A Takizawa, Y Kamikubo, S Nakamura.   

Abstract

Tissue factor is a membrane-bound glycoprotein that functions in the extrinsic pathway of blood coagulation by acting as a cofactor for factor VII, and the resulting complex leads to thrombin production in vivo. The purpose of the present study is to determine whether macrophages express tissue factor in human coronary atherosclerotic plaques. We examined directional coronary atherectomy specimens from 24 patients with unstable angina and 23 with stable exertional angina. In these specimens, macrophages were detected in 22 (92%) of 24 patients with unstable angina versus 12 (52%) of 23 with stable exertional angina (P = .003). The percentage of macrophage infiltration area was significantly larger in patients with unstable angina than in those with stable exertional angina (17 +/- 3% versus 6 +/- 2%, P = .008). The immunohistochemical double staining revealed the expression of tissue factor on macrophages in 18 (75%) of 24 patients with unstable angina versus 3 (13%) of 23 with stable exertional angina (P < .0001). Thrombus was identified in 20 (83%) of 24 patients with unstable angina versus 12 (52%) of 23 with stable exertional angina (P = .02). Fibrin deposition was mainly observed around macrophages expressing tissue factor in the patients with unstable angina. We have shown that tissue factor expression on macrophages was more frequent in coronary atherosclerotic plaques in patients with unstable angina. Tissue factor expressed on macrophages may play an important role in the thrombogenicity in coronary atherosclerotic plaques of these patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351394     DOI: 10.1161/01.atv.17.10.2232

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy.

Authors:  Michał Zabczyk; Saulius Butenas; Ilona Palka; Jadwiga Nessler; Anetta Undas
Journal:  Pol Arch Med Wewn       Date:  2010-09

2.  Comparison of ruptured coronary plaques in patients with unstable and stable clinical presentation.

Authors:  Cheol Whan Lee; Chan-Sik Park; Ilseon Hwang; Hyangsin Lee; Duk-Woo Park; Su-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Seong-Wook Park; Seung-Jung Park
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

Review 3.  Inhibitors of the initiation of coagulation.

Authors:  Ilka Ott
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 4.  Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk.

Authors:  Yunosuke Matsuura; Kohei Moribayashi; Koichi Kaikita
Journal:  J Atheroscler Thromb       Date:  2022-08-06       Impact factor: 4.394

Review 5.  Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis.

Authors:  Roberto Corti; Randolph Hutter; Juan Jose Badimon; Valentin Fuster
Journal:  J Thromb Thrombolysis       Date:  2004-02       Impact factor: 2.300

6.  Increased plasma thioredoxin in patients with acute myocardial infarction.

Authors:  Hirofumi Soejima; Hisakazu Suefuji; Shinzo Miyamoto; Ichiro Kajiwaram; Sunao Kojima; Jun Hokamaki; Tomohiro Sakamoto; Michihiro Yoshimura; Hajime Nakamura; Junji Yodoi; Hisao Ogawa
Journal:  Clin Cardiol       Date:  2003-12       Impact factor: 2.882

7.  Elevated Microparticle Tissue Factor Activity Is Associated With Carotid Artery Plaque in HIV-Infected Women.

Authors:  Juan Lin; Xiaonan Xue; Kathryn Anastos; Mardge H Cohen; Stephen J Gange; Jason M Lazar; Chenglong Liu; Wendy J Mack; Phyllis C Tien; Cathy Tilley; Howard N Hodis; Alan L Landay; Russell P Tracy; Robert C Kaplan; David B Hanna
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.771

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.